Ergocalciferol


Generic Medicine Info
Contraindications
Hypercalcaemia, metastatic calcification, evidence of vitamin D toxicity, hypervitaminosis D, abnormal sensitivity to toxic effects of vitamin D; malabsorption syndrome (unless dosed appropriately).
Special Precautions
Patient with heart disease or arteriosclerosis, renal calculi, hyperphosphataemia. Obese patients (BMI >30 kg/m2). Treatment guidelines may vary among individual products (refer to product-specific recommendations). Renal impairment. Children. Pregnancy and lactation. Monitoring Parameters Monitor serum or urinary Ca and phosphorus concentrations, and BUN initially once or twice weekly then at regular intervals; renal function as clinically indicated. Perform bone X-ray every month until the condition is stabilised and corrected. Monitor for signs and symptoms of vitamin D toxicity.
Adverse Reactions
Significant: Hypercalcaemia, soft tissue calcification, hypercalciuria, vitamin D toxicity. Gastrointestinal disorders: Nausea, abdominal pain, vomiting, constipation. General disorders and administration site conditions: Weakness. Investigations: Increased serum creatinine, weight loss. Metabolism and nutrition disorders: Anorexia, thirst. Nervous system disorders: Headache. Renal and urinary disorders: Polyuria, nocturia.
Drug Interactions
Mineral oil and colestyramine may interfere with the absorption of vitamin D. May cause hypercalcaemia with thiazide diuretics in hypoparathyroid patients. May reduce the efficacy with rifampicin and isoniazid. Metabolism may be increased by phenytoin. May increase the arrhythmogenic effects of cardiac glycosides.
ATC Classification
A11CC01 - ergocalciferol ; Belongs to the class of vitamin D and analogues. Used as dietary supplements.
Disclaimer: This information is independently developed by CIMS based on ergocalciferol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in